



\$ IFW
C.C.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

By: Robert J. Hariri Confirmation No.: 6313
Serial No.: 10/721,144 Art Unit: 1636
Filed: 25 November 2003 Examiner: McGillem, Laura L.
For: CYTOTHERAPEUTICS, Attorney Docket No.:
CYTOTHERAPEUTIC UNITS AND ANTH-0004
METHODS FOR TREATMENTS
USING THEM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of :

☒ Each U.S. patent application publication and foreign patent, except those publications not required to be submitted;

☒ Each publication or that portion which caused it to be listed on the PTO-1449, except those publications not required to be submitted;

☒ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion, except those publications not required to be submitted;

☒ all other information or portion which caused it to be listed on the PTO-1449, except those publications not required to be submitted.

1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
- ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- ☐ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
☒ enclosed

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
☐ to be charged to Jones Day Deposit Account No. 50-3013

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not

received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement.

- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .


8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)

- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability. No admission is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).


Respectfully submitted,

Date: 22 December 2005


Richard T. Girards, Jr.
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
(908) 673-9543

52,946
(Reg. No.)

LIST OF REFERENCES CITED BY APPLICANT



(Use several sheets if necessary)

ATTY DOCKET NO.

APPLICATION NO

10/721,144

APPLICANT

HARIRI, Robert J.

CONFIRMATION NO.:

6313

FILING DATE

November 25, 2003

ART UNIT:

1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			FILING DATE IF APPROPRIATE
	A1	US2001/0038836	11/08/01	During et al.			
	A2	US 2002/0123141	09/05/02	Hariri, Robert J.			
	A3	US 2002/0160510	10/31/02	Hariri, Robert J.			
	A4	US 2002/0132343	09/19/02	Lum			
	A5	US2002/0028510	03/07/02	Sanberg et al.			
	A6	US2002/0086005	07/04/02	Chiu et al.			
	A7	US2003/0180269	09/25/02	Hariri			
	A8	US 2004/0171147	09/02/04	Hariri, Robert J.			
	A9	US2005/0058631	03/17/05	Kim et al.			
	A10	3,862,002	01/21/75	Sanders			
	A11	4,829,000	05/1989	Kleinman et al.			
	A12	5,004,681	04/02/91	Boyse et al.			
	A13	5,192,553	03/09/93	Boyse et al.			
	A14	5,197,985	3/30/93	Caplan et al.			
	A15	5,226,914	7/13/93	Caplan et al.			
	A16	5,272,071	12/21/93	Chappel			
	A17	5,372,581	12/13/94	Anderson			
	A18	5,415,665	05/16/95	Hessel et al.			
	A19	5,460,964	10/24/95	McGlave et al.			
	A20	5,464,764	11/7/95	Capecchi et al.			
	A21	5,486,359	1/23/96	Caplan et al.			
	A22	5,487,992	11/7/95	Capecchi et al.			
	A23	5,516,532	5/14/96	Atala et al.			
	A24	5,591,625	1/7/97	Gerson et al.			
	A25	5,605,822	2/25/97	Emerson et al.			
	A26	5,627,059	5/6/97	Capecchi et al.			
	A27	5,635,386	6/3/97	Palsson et al.			
	A28	5,635,387	6/3/97	Fei et al.			
	A29	5,643,741	6/1/97	Tsukamoto et al.			
	A30	5,646,043	07/08/97	Emerson et al.			
	A31	5,654,186	08/05/97	Cerami et al.			
	A32	5,654,381	8/5/97	Hrkach et al.			
	A33	5,665,557	09/09/97	Murray et al.			
	A34	5,668,104	9/16/97	Nakahata et al.			
	A35	5,670,147	09/23/97	Emerson et al.			
	A36	5,670,351	09/23/97	Emerson et al.			

A37	5,672,346	9/30/97	Srour et al.			
A38	5,673,346	09/30/97	Srour et al.			
A39	5,709,854	1/20/98	Griffith-Cima et al.			
A40	5,716,616	2/10/98	Prockop et al.			
A41	5,716,794	2/10/98	Tjota et al.			
A42	5,716,827	02/10/98	Tsukamoto			
A43	5,733,541	03/31/98	Taichman et al.			
A44	5,733,542	3/31/98	Haynesworth et al.			
A45	5,744,361	4/28/98	Hoffman et al.			
A46	5,750,397	05/12/98	Tsukamoto et al.			
A47	5,763,197	6/9/98	Tsukamoto et al.			
A48	5,763,266	06/09/98	Palsson et al.			
A49	5,806,529	09/15/98	Reisner et al.			
A50	5,807,686	9/15/98	Wagner et al.			
A51	5,811,094	9/22/98	Caplan et al.			
A52	5,827,735	10/27/98	Young et al.			
A53	5,827,740	10/27/98	Pittenger			
A54	5,827,742	10/27/98	Scadden			
A55	5,837,539	11/17/98	Caplan et al.			
A56	5,849,553	12/15/98	Anderson et al.			
A57	5,851,984	12/22/98	Matthews et al.			
A58	5,858,782	1/12/99	Long et al.			
A59	5,861,315	01/19/99	Nakahata			
A60	5,866,414	02/1999	Badylak et al.			
A61	5,874,301	02/23/99	Keller et al.			
A62	5,877,299	6/2/99	Thomas et al.			
A63	5,879,318	3/9/99	Van Der Heiden et al.			
A64	5,879,940	3/9/99	Torok-Storb et al.			
A65	5,905,041	5/18/99	Beug et al.			
A66	5,906,934	5/25/99	Grande et al.			
A67	5,908,782	6/1/99	Marshak et al.			
A68	5,908,784	6/1/99	Johnstone et al.			
A69	5,914,108	6/22/99	Tsukamoto et al.			
A70	5,914,268	6/22/99	Keller et al.			
A71	5,916,202	6/29/99	Haswell			
A72	5,919,176	7/6/99	Kuypers et al.			
A73	5,922,597	7/13/99	Varfaille et al.			
A74	5,925,567	7/20/99	Kraus et al.			
A75	5,928,214	07/1999	Rubinstein et al.			
A76	5,928,947	7/27/99	Kuypers et al.			
A77	5,942,225	8/24/99	Bruder et al.			
A78	5,942,496	8/24/99	Bonadio et al.			
A79	5,958,767	9/28/99	Snyder et al.			
A80	5,962,325	10/5/99	Naughton et al.			
A81	5,968,829	10/19/99	Carpenter			

	A82	5,969,105	10/19/99	Feng et al.			
	A83	5,993,429	11/30/99	Kuypers, et al.			
	A84	5,997,860	12/7/97	Brauer et al.			
	A85	6,001,654	12/14/00	Anderson et al.			
	A86	6,010,696	1/4/00	Caplan et al.			
	A87	6,011,000	1/4/00	Faller et al.			
	A88	6,020,469	2/1/00	Hershenson			
	A89	6,022,743	2/8/00	Naughton et al.			
	A90	6,022,848	2/8/00	Kozlov et al.			
	A91	6,030,836	02/29/00	Thiede			
	A92	6,057,123	5/2/00	Craig et al.			
	A93	6,059,968	05/2000	Wolf, Jr.			
	A94	6,077,708	6/20/00	Collins et al.			
	A95	6,087,113	7/11/00	Caplan et al.			
	A96	6,093,531	7/25/00	Bjornson et al.			
	A97	6,102,871	08/15/00	Coe			
	A98	6,110,739	08/29/00	Keller <i>et al.</i>			
	A99	6,127,135	10/3/00	Hill et al.			
	A100	6,146,888	11/14/00	Smith et al.			
	A101	6,179,819	01/30/01	Haswell			
	A102	6,184,035	2/6/01	Csete et al.			
	A103	6,190,368	2/20/01	Kuypers et al.			
	A104	6,214,369	4/10/01	Grande et al.			
	A105	6,224,860	05/01/01	Brown			
	A106	6,227,202	5/8/01	Mataparkar			
	A107	6,231,880	5/15/01	Perrine			
	A108	6,248,587	6/19/01	Rodgers et al.			
	A109	6,251,383	6/26/01	Upadhyay et al.			
	A110	6,255,112	7/3/01	Thiede et al.			
	A111	6,261,549	7/17/01	Fernandez et al.			
	A112	6,280,718	08/28/01	Kaufman <i>et al.</i>			
	A113	6,300,314	10/9/01	Wallner et al.			
	A114	6,306,575	10/23/01	Thomas <i>et al.</i>			
	A115	6,312,950	11/6/01	Ohmura et al.			
	A116	6,322,784	11/27/01	Pittenger et al.			
	A117	6,326,019	12/2001	Tseng et al.			
	A118	6,326,198	12/04/01	Emerson <i>et al.</i>			
	A119	6,328,765	12/11/01	Hardwick et al.			
	A120	6,335,195	01/01/02	Rodgers <i>et al.</i>			
	A121	6,337,387	01/08/02	Sakano <i>et al.</i>			
	A122	6,338,942	1/15/02	Kraus et al.			
	A123	6,461,645	10/08/02	Boyse et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	WO 90/11354 A1	10/4/90	PCT				
	B2	WO 91/01140 A1	2/7/91	PCT				
	B3	WO 91/06667 A1	5/16/91	PCT				
	B4	WO 93/04169 A1	3/4/93	PCT				
	B5	WO 95/22611 A2&A3	08/24/95	PCT				
	B6	WO 96/34035 A2&A3	10/31/96	PCT				
	B7	WO 96/39101 A1	12/12/96	PCT				
	B8	WO 98/37903 A1	09/03/98	PCT				
	B9	WO 99/64566	12/30/99	PCT				
	B10	WO 00/17325 A1	03/30/00	PCT				
	B11	WO 00/27999 A2&A3	05/18/00	PCT				
	B12	WO 00/73421 A2&A3	12/07/00	PCT				
	B13	WO 01/93909 A2&A3	12/12/01	PCT				
	B14	WO 01/21767	03/29/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Abkowitz, Can human hematopoietic stem cells become skin, gut, or liver cells? <i>N Engl J Med.</i> 346(10):770-2, (2002)
	C2	Addison et al., "Metabolism of Prednisolone by the Isolated Perfused Human Placental Lobule", <i>J. Steroid. Biochem Mol. Biol.</i> , 39(1):83-90 (1991)
	C3	Ashihara et al., "Successful Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome," <i>Bone Marrow Transplantation</i> 24(12):1343-1345 (1999)
	C4	Barry, 1994, "Where do all the placentas go?" <i>Canadian Journal of Infection Control</i> 9(1):8-10
	C5	Belvedere et al., "Increased blood volume and CD34(+)CD38(-) progenitor cell recovery using a novel umbilical cord blood collection system," <i>Stem Cells</i> 18(4):245-251 (2000)
	C6	Bersinger et al., "Effect of Late Pregnancy Serum on the Synthesis and Release of Pregnancy Proteins by the Perfused Human Term Placenta", <i>Reprod Fertil Dev</i> 4:585-588 (1992)
	C7	Caplan, "The Mesengenic Process," <i>Clin. Plast. Surg.</i> 21(3):429-435 (1994).
	C8	Cardoso et al., "Release From Quiescence of CD34+ CD38- Human Umbilical Cord Blood Cells Reveals Their Potentiality to Engraft Adults," <i>Proc Natl Acad Sci USA</i> 90(18):8707-8711 (1993)
	C9	CD34, Medline Mesh Database, 2004.
	C10	Chen, R. & Ende, N., "The Potential for the Use of Mononuclear Cells From Human Umbilical Cord in the Treatment of Amyotrophic Lateral Sclerosis in SOD1 Mice," <i>Journal of Medicine</i> 31(1-2):21-30 (2000)
	C11	Cole et al., 1985, EBV-Hydradoma technique and its application to human lung cancer. <i>In Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc., 77-96.
	C12	Contractor et al., "A comparison of the effects of different perfusion regimens on the structure of the isolated human placental lobule," <i>Cell Tissue Res.</i> 237:609-617 (1984)
	C13	Cord Blood Stem Cell, Mesh Term Database 2003.
	C14	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens" <i>Proc Natl Acad Sci U S A.</i> 80(7):2026-30 (1983)
	C15	Czarneski, J. et al., "Effects of Cord Blood Transfer on the Hematopoietic Recovery Following Sublethal Irradiation in MRL lpr/lpr Mice," <i>Proc. Soc. Exp. Biol. Med.</i> 220(2):79-87 (1999)
	C16	Damjanov et al., Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. <i>Lab Invest.</i> 68(2):220-32 (1993)
	C17	DeLoia et al., "Effects of methotrexate on trophoblast proliferation and local immune responses." <i>Hum Reprod.</i> 13(4):1063-9 (1998)
	C18	Dorrel, "Expansion of human cord blood CD34+CD38- cells in <i>ex vivo</i> culture during retroviral transduction without a corresponding increase in SCID repopulation cell (SRC) frequency: dissociation of SRC phenotype and function," <i>Blood</i> , 95(1):102-110 (2000)
	C19	Douay et al., "Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Bone Marrow Transplant." 15(5):769-75 (1995)
	C20	Dushnik-Levinson et al. "Embryogenesis in vitro: study of differentiation of embryonic stem cells." <i>Biol Neonate.</i>

		67(2):77-83 (1995)
	C21	Elchalal et al., "Postpartum umbilical cord blood collection for transplantation: a comparison of three methods," <i>Am. J. of Obstetrics & Gyn.</i> 182(1 Pt 1):227-232 (2000)
	C22	Emerson, "Ex vivo expansion of hematopoietic precursors, progenitors and stem cells. The next generation of cellular therapeutics" <i>Blood</i> 87(8):3082-3088 (1996)
	C23	Ende, M. et al., "Hemapoetic Transplantation By Means of Fetal (Cord) Blood: A New Method," <i>Va Med Mon</i> 99:276-280 (1972)
	C24	Ende N. "Collection of Umbilical Cord Blood for Transplantation," <i>Blood</i> 80(6):1623-1624 (1992)
	C25	Ende, N. et al., "The Effect of Human Cord Blood on SJL/J Mice After Chemoablation and Irradiation and Its Possible Clinical Significance," <i>Immunol. Invest.</i> 24(6):999-1012 (1995)
	C26	Ende, "The Feasibility of Using Blood Bank Stored (4°C) Cord Blood, Unmatched for HLA for Marrow Transplantation," <i>Am. J. Clin. Pathol.</i> 111:773-781 (1999)
	C27	Ende et al., "Human Umbilical Cord Blood Effect On Sod Mice (Amyotrophic Lateral Sclerosis)," <i>Life Sci.</i> 67:53-59 (2000)
	C28	Ende et al., "Pooled Umbilical Cord Blood as a Possible Universal Donor for Marrow Reconstitution and Use in Nuclear Accidents," <i>Life Sci.</i> 69:1531-1539 (2001)
	C29	Ende, N. & Chen R., "Human Umbilical Cord Blood Cells Ameliorate Huntington's Disease in Transgenic Mice," <i>Journal of Medicine</i> 32(3-4):231-240 (2001)
	C30	Ende, N. & Chen R., "Human Umbilical Cord Blood Cells Ameliorate Alzheimer's Disease in Transgenic Mice," <i>Journal of Medicine</i> 32(3-4):241-247 (2001)
	C31	Ende, N. & Chen R., "Parkinson's Disease Mice and Human Umbilical Cord Blood," <i>Journal of Medicine</i> 33(1-4):173-180 (2002)
	C32	Ende, N., "Berashis Cells in Human Umbilical Cord Blood Vs. Embryonic Stem Cells," <i>Journal of Medicine</i> 33(1-4):167-171 (2002)
	C33	Genbacev et al. "Maternal smoking inhibits early human cytotrophoblast differentiation" <i>Reprod Toxicol.</i> 9(3):245-55 (1995)
	C34	Gluckman et al., "Cord Blood Hematopoietic Stem Cells: Bilogy and Transplantation," In: <u>Hematology, American Society of Hematology Education program Book</u> , 1998, p.1-14
	C35	Gluckman et al., "Results of Unrelated Umbilical Cord Blood Hematipoietic Stem Cell Transplant," <i>Transfusion Clinique et Biologique</i> 8(3):146-154 (2001)
	C36	Hatzopoulos et al. "Isolation and characterization of endothelial progenitor cells from mouse embryos." <i>Development</i> 125(8):1457-68 (1998)
	C37	Himori, et al. "Chemotherapeutic susceptibility of human bone marrow progenitor cells and human myelogenous leukemia cells (HL-60) in co-culture: preliminary report." <i>Int J Cell Cloning</i> 2(4):254-62 (1984)
	C38	Hirashima et al. "Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis." <i>Blood</i> 93(4):1253-63 (1999)
	C39	Hows "Status of Umbilical Cord Blood Transplantation in the Year 2001," <i>J Clin Pathol</i> 54(6):428-434 (2001)
	C40	Keown et al., "Methods for introducing DNA into mammalian cells." <i>Methods Enzymol.</i> 185:527-37 (1990)
	C41	Kondo et al., "Reduced Interferon Gamma Production by Antigen-Stimulated Cord Blood Mononuclear Cells is a Risk Factor of Allergic Disorders - 6-Year Follow-up Study," <i>Clin Exp Allergy</i> 28(11):1340-1344 (1998)
	C42	Korbling et al., "Peripheral Blood Stem Cell Versus Bone Marrow Allotransplantation: Does the Source of Hematopoietic Stem Cells Matter?" <i>Blood</i> 98(10):2900-2908 (2001)
	C43	Korbling et al., "Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells." <i>N Engl J Med.</i> 346(10):738-46 (2002)
	C44	Kozbor et al., "The production of monoclonal antibodies from human lymphocytes." <i>Immunology Today</i> 4, 72-79 (1983)
	C45	Kurtzberg et al., <i>New Eng J Med</i> 335:157-166 (1996)
	C46	Larsson et al., <i>Angiogenesis</i> 5,107-110 (2002)
	C47	Lowy et al. 1980, "Isolation of transforming DNA: cloning the hamster aprt gene." <i>Cell</i> 22(3):817-23.
	C48	Ma et al., <i>Tissue Engineering</i> 5:91-102 (1999)
	C49	Melchner, et al., "Human placental conditioned medium reverses apparent commitment to differentiation of human promyelocytic leukemia cells (HL60)." <i>Blood</i> 66(6):1469-72 (1985)
	C50	Minguel et al., <i>Exp Biol Med</i> 226:507-520 (2001)
	C51	Moore et al., "A simple perfusion technique for isolation of maternal intervillous blood mononuclear cells from human placentae," <i>J. Immunol. Methods</i> 209(1):93-104 (1997)
	C52	Muhlemann et al., <i>Placenta</i> 16:367-373 (1995)
	C53	Mulligan and Berg, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase." <i>Proc Natl Acad Sci U S A.</i> 78(4):2072-6 (1981)
	C54	Myllinen, "In Search of Models for Hepatic and Placental Pharmacokinetics, dissertation, University of Oulu (2003)
	C55	Nadkarni et al. "Effect of retinoic acid on bone-marrow committed stem cells (CFU-c) from chronic myeloid leukemia

	patients." <i>Tumori</i> 70(6):503-5 (1984)
C56	O'Hare et al. "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase." <i>Proc Natl Acad Sci U S A</i> . 78(3):1527-31 (1981)
C57	Ordi et al., <i>Am J Surg Pathol</i> 8:1006-1011 (1998)
C58	Papaioannou et al., <i>Stem Cell Handbook</i> 2004, 19-31.
C59	Placenta, <i>Encyclopediia Britanica</i> , 2003.
C60	Placenta, <i>Mesh, Pubmed</i> , 2003
C61	Rameshwar et al., "Endogenous Hematopoietic Reconstitution Induced by Human Umbilical Cord Blood Cells in Immunocompromised Mice: Implications for Adoptive Therapy," <i>Experimental Hematology</i> 27:176-185 (1999)
C62	Ray et al., "CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family." <i>J Biol Chem</i> . 1997 Jul 25;272(30):18702-8 (1997)
C63	Reyes et al. "Origin of endothelial progenitors in human postnatal bone marrow." <i>J Clin Invest</i> . 109(3):337-46 (2002)
C64	Sakabe et al., "Functional Differences Between Subpopulations of Mobilized Peripheral Blood-Derived CD34+ Cells Expressing Different Levels of HLA-DR, CD33, CD38 and c-kit Antigens," <i>Stem Cells</i> 15(11):73-81 (1997)
C65	Santerre et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells." <i>Gene</i> 30(1-3):147-56 (1984)
C66	Shamblott, et al., "Derivation of pluripotent stem cells from cultured human primordial germ cells." <i>Proc Natl Acad Sci U S A</i> 95(23):13726-31 (1998)
C67	Slager "Transforming growth factor-beta in the early mouse embryo: implications for the regulation of muscle formation and implantation." <i>Dev Genet</i> . 14(3):212-24 (1993)
C68	Smithies et al. "Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination." <i>Nature</i> 317(6034):230-4 (1985)
C69	Srour, "Ex vivo expansion of hematopoietic stem and progenitor cells. Are we there yet?" <i>The Journal of Hematotherapy</i> 8:93-102 (1999)
C70	Szybalska and Szybalska, "Genetics of human cell lines IV: DNA-mediated heritable transformation of a biochemical trait." <i>Proc Natl Acad Sci U S A</i> 48: 2026-2034 (1962)
C71	Tissue culture: <i>Merriam-Webster's Online Dictionary</i> , 2004.
C72	Thomas and Capecchi, "Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells." <i>Cell</i> 51(3):503-12 (1987)
C73	Thompson et al., 1998 "Embryonic stem cell lines derived from human blastocysts." <i>Science</i> .282 (5391): 1145-7 (1998)
C74	Totipotent stem cells, <i>Stem Cells Information Center On-line</i> , 2004.
C75	Totipotent stem cells, <i>Medline Mesh Database</i> , 2004.
C76	Tremblay et al., "Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta." <i>Genes Dev</i> . 15(7):833-8 (2001)
C77	Turner et al., "A modified harvest technique for cord blood hematopoietic stem cells," <i>Bone Marrow Transplantation</i> 10:89-91 (1992)
C78	Uchimura et al. "Human N-acetylglucosamine-6-O-sulfotransferase involved in the biosynthesis of 6-sulfo sialyl Lewis X: molecular cloning, chromosomal mapping, and expression in various organs and tumor cells." <i>J Biochem (Tokyo)</i> . 124(3):670-8 (1998)
C79	Van Bekkum, "The Pluripotent Hemopoietic Stem Cell: Its Identification and Applications," <i>Verh. Dtsch. Ges. Pathol.</i> 74:19-24 (1990)
C80	Viacord, <i>Umbilical Cord Blood Can Save Lives</i> (Information brochure), Boston: ViaCell CENTR-BRO R1 10/01 (2001)
C81	Vilmer et al., "HLA-Mismatched Cord Blood Transplantation: Immunological Studies," <i>Blood Cells</i> 20(2-3):235-241 (1994)
C82	Wang et al., "Enhanced Recovery of Hemapoietic Progenitor and Stem Cells from Cultivated, Postpartum Human Placenta," <i>Blood</i> 68:183, abstract 769 (2001)
C83	Wigler et al. "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells." <i>Cell</i> 11(1):223-32 (1997)
C84	Yan et al., "Retinoic acid promotes differentiation of trophoblast stem cells to a giant cell fate." <i>Dev Biol</i> . 235(2):422-32 (2001)
C85	Ye et al., "Recovery of placental-derived adherent cells with mesenchymal stem cell characteristics," <i>Blood</i> 98(11/1):147b Abstract no. 4260 (2001)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	